ERADICATE PATHOGENS AND SUBVERT FUTURE RESISTANCE

ALTABAX is a prescription topical antibacterial for impetigo that targets Staphylococcus aureus and Streptococcus pyogenes in your patients.

*Retapamulin is bacteriostatic against Staphylococcus aureus and Streptococcus pyogenes. At concentrations 1,000 times the in vitro MIC, retapamulin is bactericidal against these same organisms.

Important Safety Information

ALTABAX is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes.

The most common drug-related adverse reaction was application site irritation (1.4% of patients).

Please see complete Prescribing Information for ALTABAX

References:
  1. Kosowska-Shick K, Clark C, Credito K, et al. Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother. 2006;50:765-769.
  2. Koning S, van der Wouden JC, Chosidow O, et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol. 2008;158:1077-1082.
  3. Data on file ABX107, GlaxoSmithKline.